Facebook
Twitter
LinkedIn
ForwardBest Practices and Emerging Therapies for Myelodysplastic Syndromes (MDS)
Activity description
This activity consists of recorded presentations from the "27th Annual National Conference" held Oct. 15–17, 2018, in Minneapolis, Minn.
According to the American Cancer Society, approximately 10,000 people in the United States are diagnosed with MDS each year. Survival can be as high as six years in lower-risk patients and as low as less than six months in higher-risk patients. MDS also carries the risk of transforming into acute myeloid leukemia, although the majority of deaths are caused by MDS itself or related complications. The prevalence of MDS is highest in older individuals, and the incidence of MDS is expected to rise with the aging population.
Treatment options for MDS are limited and only 4 percent of patients with MDS are considered for hematopoietic stem cell transplant (HSCT). Emerging agents may expand the treatment options for MDS patients, and there are several in late-stage clinical trials. This presentation will review the most current, evidence-based guidelines and practices for the management of MDS, including advances in HSCT as a treatment option. Emerging therapies for MDS that have shown promise in clinical trials will also be discussed.
Provided by
This activity is provided by OptumHealth Education.
Commercial support
There was no commercial support received for this activity.
Required hardware/software
To view this activity, you will need Internet Explorer 7.0+ or Firefox 3.0+ with Windows Media Player 9+, RealPlayer 12+ or Adobe Flash Player 9+. Be sure to disable any pop-up blocking software prior to beginning this activity.
Target Audience
This activity is designed to meet the educational needs of case managers, nurses, pharmacists, pharmacy technicians, physicians and other health care professionals who are interested in MDS.
Learning Objectives
At the end of this educational activity, participants should be able to:
- Describe the emerging novel and targeted therapies for MDS that are in late-stage or phase-three clinical trials.
- Discuss genetic prognostic factors that may help guide management of MDS using HSCT.
- Review the current guidelines and evidence-based practices for the management of MDS.
Additional Information
| Attachment | Size |
|---|---|
 Best Practices & Emerging Therapies for MDS Handouts | 5.63 MB |
Faculty
 | Erica Warlick, MD |
Planning Committee
Michael Abecassis, MD, MBA
J. Roscoe Miller Distinguished Professor
Departments of Surgery and Microbiology/Immunology
Feinberg School of Medicine, Northwestern University;
Chief, Division of Organ Transplantation
Northwestern Memorial Hospital;
Founding Director, Comprehensive Transplant Center
Northwestern University
Chicago, IL
Sarah Chart, RN
Senior Director
OptumHealth Education
Eden Prairie, MN
Dixon B. Kaufman, MD, PhD, FACS
Ray D. Owens Professor of Surgery
Chief, Division of Transplantation
University of Wisconsin School of Medicine and Public Health;
University Hospital
Madison, WI
Rebecca Gleason, RN, CCM
Activity Manager
OptumHealth Education
Eden Prairie, MN
Tina Rydland, PharmD
Crystal Clear Rx
Denver, CO
Crystal Wong, MD
President Propoint Medical Writing
Wexford, PA
Disclosures of relevant financial relationships
In accordance with the ACCME Standards for Commercial SupportSM, OptumHealth Education (OHE) requires all those involved in the development of activity content to disclose their relevant financial relationships. An individual has a relevant financial relationship if such person (or his/her spouse/partner) has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services relate to the activity content. OHE ensures that the content is independent of commercial bias.
Ms. Chart and Ms. Gleason have indicated that they are employees of and own stock in UnitedHealth Group.
Dr. Wong has indicated that she has received grant/research support from MyoKardia.
The remaining activity faculty or planners have no financial relationships to disclose.
Method for calculating CE credit
CE credit was calculated by the complexity of content.
Accreditation Statement
In support of improving patient care, OptumHealth Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team.
Credit Designation Statements
Nurses
The participant will be awarded up to 1.00 contact hour(s) of credit for attendance and completion of supplemental materials.
Nurse practitioners
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts credit from organizations accredited by the ACCME and ANCC.
Pharmacists/Pharmacy technicians
This activity is approved for 1.00 contact hour(s) ([0.10] CEU) in states that recognize ACPE.
Attending the full program will earn 1.00 contact hour(s).
Unique Activity Number(s): JA0007123-0000-19-037-H01-P/T
Physicians
OptumHealth Education designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
PAs
The American Academy of Physician Assistants (AAPA) accepts credit from organizations accredited by the ACCME.
Case managers
The Commission for Case Manager Certification has approved this program for a maximum of 1.00 clock hour(s) for Certified Case Managers (CCM).
Attendance
A certificate of attendance will be provided to learners upon completion of activity requirements, enabling participants to register with licensing boards or associations that have not been preapproved for credits. To apply for credit types not listed above, participants should use the procedure established by the specific organization with which they wish to obtain credit.
Available Credit
- 1.00 ACPE - Pharmacists
- 1.00 ACPE - Pharmacy Technicians
- 1.00 AMA - Physicians
- 1.00 ANCC - Nurses
- 1.00 Attendance - General Attendance
- 1.00 CCMC - General - Case Managers
You must be logged into your account to participate in this activity. Get started by clicking “Begin/Continue” and viewing the “CE Info”; then follow the prompts at the bottom of the screen. At the end of the activity, you will be able to view, save or print your certificate of participation. A complete listing of all of your activities can be found under “My Account”, “My Activities.”